You can narrow down the results using the filters
-
Investigating Type 2 Diabetes after Gestational Diabetes: the DIVINE-NSW study.
Expand descriptionThis project lays the foundations for an Australian trial to test the usefulness and safety of drug therapies to prevent the development of long-term diabetes among women who develop diabetes in pregnancy, gestational diabetes mellitus (GDM). GDM, previously considered a transient condition, is now an established risk factor for long-term diabetes. Women whose blood sugar levels do not return to normal soon after giving birth are at particularly high risk of developing established diabetes and consequent heart and blood vessel disease. Lifestyle interventions may help, but they are hard for busy mothers to adopt and sustain. Even with lifestyle interventions, these women still have substantial “residual risk”, warranting investigation of preventive drug therapies. Currently, clinical guidelines do not recommend routine use of medications because of the lack of adequate research. Our proposed research will provide critical information that will form the basis of a substantial Australian contribution to global research efforts in diabetes. Our research will: - Identify all women who were diagnosed with GDM from three (3) Sydney hospitals in the past 3 years and invite them to complete an online questionnaire and, if long-term diabetes has not already developed, to undergo a blood test to evaluate their glucose status. - Invite a sample of women to participate in interviews to understand their perspectives of GDM, long-term risks and willingness to take preventive medications (including willingness to participate in trials of preventive medicines). - Conduct interviews with healthcare providers to understand their views of long-term diabetes risk, screening and preventive strategies for women with GDM. Collectively, this study will provide a contemporary snapshot of post-GDM care and outcomes from a diverse Australian population who receive obstetric care at large urban hospitals. These data will critically inform the design and conduct of a large-scale trial of preventive medications in this and similar populations.
-
A single session intervention for anxiety and depression: a randomised controlled trial
Expand descriptionThe primary aim of this project is to determine whether a single session intervention is no less effective (i.e., non-inferior) in reducing anxiety and depressive symptoms compared to a multi-session intervention, the Wellbeing Course. The secondary aim of this project is to determine whether the single session intervention is more effective than a waitlist control group. Participants in the SSI will receive access to a single online lesson and will be invited to contact the clinician within the 1-week following the release of the lesson. Participants in the MSI will receive access to the 8-week intervention and contact with the clinician. Participants in the Waitlist Control Group will receive access to the MSI following the 8-week waitlist period. All participants will complete questionnaires at assessment, pre-treatment, and then 4-weeks, 8-weeks, and 17-weeks later. The primary endpoint will be 8-weeks after pre-treatment (i.e., Week 9).
-
An evaluation of the efficacy of eptinezumab in the inpatient management of status migrainosus in comparison to intravenous lignocaine in patients who have failed other therapies
Expand descriptionThis study is a randomised, double-blinded parallel group controlled study to evaluate the safety and efficacy of eptinezumab against lignocaine in the inpatient treatment of status migrainosus. Subjects who fulfil the International Classification of Headache Disorders, third edition criteria of migraine and status migrainosus and who have failed or are inappropriate to receive triptan and chlorpromazine therapy will be enrolled into this trial. Upon randomisation, forty subjects will be allocated in a 1:1 ratio to receive either eptinezumab 300mg or placebo infusion, and admitted to hospital to receive intravenous lignocaine as standard medical therapy (if they received a placebo infusion on randomisation), or a placebo infusion for up to five days, or until their migraine is successfully treated.
-
Cognitive Orientation to daily Occupational Performance Approach (CO-OP) for children on the autism spectrum
Expand descriptionCognitive Orientation to daily Occupational Performance Approach TM (CO-OP) was developed to support motor skill development of children with motor difficulties. This study is a randomised controlled trial to test the acceptability, feasibility, and efficacy of the CO-OP motor skill intervention program in children with autism and motor difficulties aged 5-10 years (n = 30). Following the initial intake assessment and goal setting (session 1), participants will be randomised to receive either the immediate CO-OP intervention (n = 15) or be waitlisted to receive the CO-OP intervention (n = 15). Families in the immediate CO-OP group will receive the full intervention protocol immediately following the intake session (8*1hr weekly CO-OP sessions – Sessions 2-9), while families in the waitlist group will not receive any active intervention during this first 8 week block, however, they can continue to access any clinical services that they would usually access. After the follow up assessment (session 10 for immediate CO-OP group, session 2 for waitlist group), the waitlist group will complete the CO-OP therapy (sessions 3-10) and attend a follow up assessment session (session 11), It is expected that at the conclusion of the intervention, children undertaking CO-OP will have improvements on the performance and satisfaction of their movement-based goals.
-
Learning to Thrive: Investigating the effects of an online intervention program for university students' mental health and well-being
Expand descriptionObjectives: To investigate the effectiveness of an online intervention program Learning to Thrive for university students mental health and well-being. Hypotheses: (1) Compared to the control condition, participants in the intervention conditions will show lower levels of anxiety, depression, academic worry, social anxiety, loneliness, trait avoidance, and intolerance of uncertainty, as well as higher life-satisfaction at post-intervention, at three- and six-month follow-ups. (2) The change scores of both behavioural activation, self-compassion and social identification from pre- to post-intervention will mediate the intervention effects on the outcomes at post-intervention, and at three- and six-month follow-ups.
-
A comparison of wound healing in diabetic foot wounds using a Biodegradable Temporising Matrix (BTM) scaffold technology versus usual standard of care.
Expand descriptionThis research project aims to assess the impact of a wound healing technology (NovoSorb® BTM) on the rate of wound healing in participants who need to undergo minor amputation of their foot. A minor amputation is a procedure which is required to be performed when there is infection or damage to the tissue of the foot which is no longer able to be salvaged or healed without surgery. A minor amputation may involve one or more of your toes or a portion of your foot which has become damaged and is not able to be saved or healed without removal (amputation) of the affected tissue. Ischemia is a condition where parts of the body are starved of blood, which provide oxygen and nutrients for survival, in turn resulting in damage to tissue which can result in wounds. Neuro-ischemia is a condition most often suffered by people with diabetes. This condition affects both the large and small blood vessels in your body, which results in ischemia to tissues. In people with diabetes this condition often affects the blood vessels in their feet which can lead to non-healing wounds. This study seeks to test the ability of the NovoSorb® BTM to heal wounds in people with wounds related to neuro-ischemia. NovoSorb® BTM was originally designed for use in healing wounds in burns patients. The technology has proven useful in helping to heal burns wounds for more than 5 years. This technology is a piece of foam which serves as a scaffold for your healing tissue to grow through. The product is applied by a surgeon in a theatre environment and is left in place until your tissue has grown through the foam scaffold. The foam is specially formulated to slowly dissolve as your healing progresses and your tissue gets stronger. The foam is absorbed by your body and is considered safe and non-toxic. We are seeking to assess whether NovoSorb® BTM helps to heal minor amputation wounds faster and with less risk of infection when compared with current practice (standard wound dressings – negative pressure and antimicrobial dressings). Medications, drugs, and devices must be approved for use by the Australian Federal Government. NovoSorb® BTM is approved in Australia to treat wounds.
-
Online eTherapy Program for Individuals with binge-eating disorder
Expand descriptionThe study will evaluate the effectiveness of a new interactive online Cognitive Behavioural Therapy program for individuals who experience difficulty with binge eating, named Binge Eating eTherapy or BEeT. BEeT consists of ten, one-hour interactive, multi-media sessions with all core components of CBT demonstrated effective in eating disorders, including establishing regular eating according to the “three-hour rule” and self-monitoring, thought challenging and feared food exposure. The study will examine whether engaging with BEeT results in a significant decrease in individuals' binge eating in those with binge-eating disorder.
-
Effect of pre-sleep alpha-lactalbumin supplementation in a trained population with sleep difficulties
Expand descriptionSleep improves the health, well-being and performance of individuals undergoing training, so this study aims to investigate a practical nutritional aid in attempt to improve sleep quality. The impact of diet on sleep is a growing area of research interest, with reports that protein intakes high in tryptophan may benefit sleep, especially for those experiencing sleep complaints. In addition to sleep, the intake of alpha-lactalbumin may improve mood and cognitive performance of an individual. The proposed mechanism by which sleep, mood and cognition are affected is through increases in tryptophan availability to the brain, which can be measured through blood plasma concentrations. The effect of alpha-lactalbumin intake on these measures has not been completed within a trained population with sleep difficulties. Therefore, we are testing the hypotheses that alpha-lactalbumin supplementation in the evening will improve sleep characteristics, mood, and cognitive performance of trained individuals with sleep difficulties.
-
Determining the effectiveness of vestibular (balance) and ocular (eye movement) motor function screening assessments for identifying sleepy drivers.
Expand descriptionThis project will investigate how VOMS assessments, measured by the Neuroflex®, can identify sleepiness that affects the performance of driving tasks. Your participation in this project will involve visiting the Flinders Health and Medical Research Institute Sleep Health group laboratory (located in the Mark Oliphant Building, Bedford Park) for a 2-hour introductory laboratory visit. You will then be asked to complete 7-days of monitoring of your sleep and daytime activity at home with an activity monitor worn on your wrist before returning to the laboratory. During your experimental laboratory visit you will first undergo an overnight sleep study followed by the next day and night of performance testing until you finish the protocol at 1pm (i.e., 2 nights and 1.5 days in the laboratory)
-
Regional vs Intravenous Lidocaine in Determining functional outcome after Lung Surgery (RIDDLE)
Expand descriptionSubstantial persistent pain after major lung surgery remains a significant problem despite new methods of pain control with up to one third of these patients still experiencing pain severe enough to affect their daily living months after lung surgeries. In addition to its effect on the essential daily tasks of living, long term pain is also known to cause mental health problems and lead to long-term opioid dependency further affecting the quality of life of patients and incurring extra cost to the healthcare system. Optimization of the acute pain control immediately after surgery is the single most important factor affecting the development of long-term pain. One of the more recently developed techniques of pain control is a technique called regional anaesthesia whereby local anaesthetic is injected next to the nerves supplying that area of the body with the surgical incision, thereby effectively ‘numbing’ them to reduce the pain felt by the patients. An alternative pain relief technique involves giving a small dose of local anaesthetic, such as lidocaine, directly into the veins of the patient. This method can offer a much more predictable pain relief than a regional anaesthetic technique because it does not require the specialized technical skills to perform and hence it may have a great potential for general use to reduce pain effectively. Nonetheless, administering local anaesthetic agent, such as lidocaine, directly into the blood can still have some rare side effect including drowsiness and changes in heart rhythm and blood pressure. In this study, we aim to compare these two pain relief methods, not only to assess whether one is better than the other in relieving pain, but also whether one is better to allow the patients to recover from surgery.